Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients

Blood Purif. 2019;47 Suppl 2(Suppl 1):31-37. doi: 10.1159/000496634. Epub 2019 Apr 3.

Abstract

Background/aims: There is lack of definitive evidence about the association between erythropoiesis-stimulating agent (ESA) responsiveness in the pre-dialysis phase and mortality. Therefore, we conducted a hospital-based, retrospective, cohort study to assess the predictive value of ESA response for prognosis in incident hemodialysis patients.

Methods: A total of 108 patients without preexisting cardiovascular disease who had been started on maintenance hemodialysis were studied. ESA responsiveness just before starting dialysis was estimated using an erythropoietin resistance index (ERI). The endpoint was defined as all-cause death.

Results: During a mean follow-up period of 3.1 ± 1.6 years, 18 (17%) patients died. Overall, the multivariate Cox regression analysis revealed that the log-transformed ERI remained an independent predictor of all-cause death after adjustment using a propensity score (hazard ratio 2.25, 95% CI 1.25-4.06).

Conclusions: Among incident hemodialysis patients, hyporesponsiveness to ESA may be associated with mortality.

Keywords: Anemia; End-stage kidney disease; Erythropoiesis-stimulating agent; Erythropoietin; Hemodialysis; Mortality.

MeSH terms

  • Aged
  • Anemia / complications*
  • Anemia / drug therapy*
  • Anemia / mortality
  • Erythropoiesis / drug effects
  • Female
  • Hematinics / therapeutic use*
  • Humans
  • Japan
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Renal Dialysis* / mortality
  • Retrospective Studies

Substances

  • Hematinics